Shares of Bristol-Myers Squibb Co.  (BMY) shot out of a cannon Thursday, racing higher by 5.55% to $68.98.

Earlier this month the company beat on earnings per share and revenue expectations, but it was a new price target that spurred shares higher Thursday. Morgan Stanley analyst David Risinger slapped a $78 price target on the stock, the highest on Wall Street.

However, Risinger isn't the only bull. Citigroup's Andrew Baum matched Risinger's price target just a day later, putting a $78 target on Bristol-Myers stock Friday. He laid out a scenario where Pfizer (PFE) may look to buy the company despite its $112 billion market cap.

He views the odds of a takeover at 65%, up from 50%. Baum says there are three catalysts for a potential takeover:

  1. "Revenue potential in non-small cell lung cancer is partly de-risked" thanks to its "Checkmate-227 tumor mutation burden data."
  2. Its recent collaboration and equity stake in Nektar Therapeutics (NKTR) could boost market share for Opdivo.
  3. Given that Pfizer's immuno-oncology efforts are looking "increasing suspect," acquiring Bristol-Myers could be its last chance at eating a meaningful piece of the annual $50 billion immuno-oncology pie.

From current levels, Risinger and Baum's price target implies more than 12% upside. For Risinger's part, he was optimistic on the company's prospects of treating first-line lung cancer with a combination of its Opdivo and Yervoy treatments.

Despite extending the highs it set on Thursday, Bristol-Myers stock ultimately finished flat on the day, falling 0.087% on the day to $68.97. Pfizer on the other hand closed higher by 1.54%, closing at $36.26. 

Notably, Bristol-Myers stock also pays a 2.3% dividend yield.

This article is commentary by an independent contributor. At the time of publication, the author had no positions in the stocks mentioned.

More from Stocks

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Tech Stock Predictions for 2019

Tech Stock Predictions for 2019

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Jim Cramer Says That This Is a Question All Investors Must Ask Themselves

Jim Cramer Says That This Is a Question All Investors Must Ask Themselves

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know

Elon Musk, Carlos Ghosn, Huawei and Gilead Sciences - 5 Things You Must Know